SYSTEMIC LUPUS ERYTHEMATOSUS – PAST, PRESENT AND EMERGING THERAPIES
DOI:
https://doi.org/10.31435/ijitss.3(51).2026.6274Keywords:
Systemic Lupus Erythematosus, Treatment, CAR T-cell, Biologic TherapyAbstract
Background Systemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disease characterized by immune dysregulation, autoantibody production, and immune complex-mediated tissue damage. Despite advances in disease management, SLE remains associated with substantial morbidity, increased mortality, and significant therapeutic challenges.
Objective This narrative review summarizes the current understanding of SLE epidemiology, pathogenesis, diagnosis, and treatment, with a particular focus on established therapeutic strategies and emerging treatment modalities.
Methods A comprehensive literature search was conducted using publicly available scientific databases. Clinical guidelines, systematic reviews, meta-analyses, and original research articles were selected based on their relevance to SLE pathogenesis, diagnosis, and treatment.
Results Current management of SLE aims to achieve remission or low disease activity through the use of hydroxychloroquine, glucocorticoids, conventional immunosuppressive agents, and targeted biologic therapies, including belimumab and anifrolumab. Improved understanding of SLE immunopathogenesis has facilitated the development of novel therapeutic approaches. Among these, hematopoietic stem cell transplantation and chimeric antigen receptor (CAR) T-cell therapy have demonstrated encouraging results in patients with severe or treatment-refractory disease. However, their widespread implementation is currently limited by safety concerns, treatment-related toxicity, high cost, limited clinical experience, and the absence of long-term efficacy and safety data.
Conclusions Although recent therapeutic advances have improved clinical outcomes in SLE, many patients continue to experience refractory disease and treatment-related complications. Emerging therapies offer the potential for more targeted and durable disease control, but further large-scale clinical studies with extended follow-up are required to establish their long-term efficacy, safety, and place in future treatment algorithms.
References
Stojan, G., & Petri, M. (2018). Epidemiology of systemic lupus erythematosus: An update. Curr Opin Rheumatol, 30(2), 144–150. https://doi.org/10.1097/bor.0000000000000480
Barber, M.R.W., et al. (2021). Global epidemiology of systemic lupus erythematosus. Nat Rev Rheumatol, 17(9), 515–532. https://doi.org/10.1038/s41584–021–00668–1
Accapezzato, D., et al. (2023). Advances in the pathogenesis and treatment of systemic lupus erythematosus. Int J Mol Sci, 24(7). https://doi.org/10.3390/ijms24076578
Dai, X., Fan, Y., & Zhao, X. (2025). Systemic lupus erythematosus: Updated insights on the pathogenesis, diagnosis, prevention and therapeutics. Signal Transduct Target Ther, 10(1), 102. https://doi.org/10.1038/s41392–025–02168–0
Coss, S.L., et al. (2023). The complement system and human autoimmune diseases. J Autoimmun, 137, 102979. https://doi.org/10.1016/j.jaut.2022.102979
Tanaka, Y., Kusuda, M., & Yamaguchi, Y. (2023). Interferons and systemic lupus erythematosus: Pathogenesis, clinical features, and treatments in interferon-driven disease. Mod Rheumatol, 33(5), 857–867. https://doi.org/10.1093/mr/roac140
Crowl, J.T., et al. (2017). Intracellular nucleic acid detection in autoimmunity. Annu Rev Immunol, 35, 313–336. https://doi.org/10.1146/annurev-immunol-051116–052331
Xu, H., et al. (2024). Cellular spermine targets JAK signaling to restrain cytokine-mediated autoimmunity. Immunity, 57(8), 1796–1811.e8. https://doi.org/10.1016/j.immuni.2024.05.025
Skopelja-Gardner, S., et al. (2020). The early local and systemic type I interferon responses to ultraviolet B light exposure are cGAS dependent. Sci Rep, 10(1), 7908. https://doi.org/10.1038/s41598–020–64865-w
Crow, M.K. (2023). Pathogenesis of systemic lupus erythematosus: Risks, mechanisms and therapeutic targets. Ann Rheum Dis, 82(8), 999–1014. https://doi.org/10.1136/ard-2022–223741
Fava, A., & Petri, M. (2019). Systemic lupus erythematosus: Diagnosis and clinical management. J Autoimmun, 96, 1–13. https://doi.org/10.1016/j.jaut.2018.11.001
Kraak, J.H., et al. (1965). The value of hydroxychloroquine (PLAQUENIL) for the treatment of chronic discoid lupus erythematosus; a double blind trial. Dermatologica, 130, 293–305. https://doi.org/10.1159/000254544
Davies, J.H. (1929). Treatment of lupus erythematosus with gold compounds. Br Med J, 1(3548), 12–3. https://doi.org/10.1136/bmj.1.3548.12
Hench, P.S., et al. (1949). The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone: Compound E) and of pituitary adrenocortical hormone in arthritis: Preliminary report. Ann Rheum Dis, 8(2), 97–104. https://doi.org/10.1136/ard.8.2.97
Austin, H.A., 3rd, et al. (1986). Therapy of lupus nephritis. controlled trial of prednisone and cytotoxic drugs. N Engl J Med, 314(10), 614–9. https://doi.org/10.1056/nejm198603063141004
Sztejnbok, M., et al. (1971). Azathioprine in the treatment of systemic lupus erythematosus. A controlled study. Arthritis Rheum, 14(5), 639–45. https://doi.org/10.1002/art.1780140511
Chan, T.M., et al. (2000). Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. hong Kong-Guangzhou nephrology study group. N Engl J Med, 343(16), 1156–62. https://doi.org/10.1056/nejm200010193431604
Merrill, J.T., et al. (2010). Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum, 62(1), 222–33. https://doi.org/10.1002/art.27233
Rovin, B.H., et al. (2012). Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study. Arthritis Rheum, 64(4), 1215–26. https://doi.org/10.1002/art.34359
Furie, R., et al. (2011). A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum, 63(12), 3918–30. https://doi.org/10.1002/art.30613
Morand, E.F., et al. (2020). Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med, 382(3), 211–221. https://doi.org/10.1056/NEJMoa1912196
Furie, R.A., et al. (2019). Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): A randomised, controlled, phase 3 trial. Lancet Rheumatol, 1(4), e208-e219. https://doi.org/10.1016/s2665–9913(19)30076–1
Bertsias, G., et al. (2008). EULAR recommendations for the management of systemic lupus erythematosus. report of a task force of the EULAR standing committee for international clinical studies including therapeutics. Annals of the Rheumatic Diseases, 67(2), 195–205. https://doi.org/10.1136/ard.2007.070367
Fanouriakis, A., et al. (2019). 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Annals of the Rheumatic Diseases, 78(6), 736–745. https://doi.org/10.1136/annrheumdis-2019–215089
Fanouriakis, A., et al. (2024). EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis, 83(1), 15–29. https://doi.org/10.1136/ard-2023–224762
van Vollenhoven, R., et al. (2017). A framework for remission in SLE: Consensus findings from a large international task force on definitions of remission in SLE (DORIS). Ann Rheum Dis, 76(3), 554–561. https://doi.org/10.1136/annrheumdis-2016–209519
Franklyn, K., et al. (2016). Definition and initial validation of a lupus low disease activity state (LLDAS). Annals of the Rheumatic Diseases, 75(9), 1615–1621. https://doi.org/10.1136/annrheumdis-2015–207726
Parodis, I., et al. (2024). EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis. Annals of the Rheumatic Diseases, 83(6), 720–729. https://doi.org/10.1136/ard-2023–224416
Parodis, I., et al. (2017). Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus. Autoimmunity Reviews, 16(4), 343–351. https://doi.org/10.1016/j.autrev.2017.02.005
Chasset, F., et al. (2015). Influence of smoking on the efficacy of antimalarials in cutaneous lupus: A meta-analysis of the literature. Journal of the American Academy of Dermatology, 72(4), 634–639. https://doi.org/10.1016/j.jaad.2014.12.025
Islam, M.A., et al. (2020). Immunomodulatory effects of diet and nutrients in systemic lupus erythematosus (SLE): A systematic review. Front Immunol, 11, 1477. https://doi.org/10.3389/fimmu.2020.01477
Jiao, H., et al. (2022). Diet and systemic lupus erythematosus (SLE): From supplementation to intervention. Int J Environ Res Public Health, 19(19). https://doi.org/10.3390/ijerph191911895
Blaess, J., et al. (2024). Recommendations for physical activity and exercise in persons living with systemic lupus erythematosus (SLE): Consensus by an international task force. RMD Open, 10(2). https://doi.org/10.1136/rmdopen-2024–004171
Alexander, T., et al. (2025). Autologous haematopoietic stem cell transplantation for rheumatic diseases: Best practice recommendations from the EBMT practice harmonization and guidelines committee. Bone Marrow Transplant, 60(11), 1451–1464. https://doi.org/10.1038/s41409–025–02695-y
Alexander, T., & Greco, R. (2022). Hematopoietic stem cell transplantation and cellular therapies for autoimmune diseases: Overview and future considerations from the autoimmune diseases working party (ADWP) of the european society for blood and marrow transplantation (EBMT). Bone Marrow Transplantation, 57(7), 1055–1062. https://doi.org/10.1038/s41409–022–01702-w
Suresh, N., et al. (2026). Hematopoietic stem cell transplantation in rheumatic diseases. International Journal of Rheumatic Diseases, 29. https://doi.org/10.1111/1756–185x.70604
Mougiakakos, D., et al. (2021). CD19-Targeted CAR T cells in refractory systemic lupus erythematosus. New England Journal of Medicine, 385(6), 567–569. https://doi.org/10.1056/NEJMc2107725
Mackensen, A., et al. (2022). Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nature Medicine, 28(10), 2124–2132. https://doi.org/10.1038/s41591–022–02017–5
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Jakub Zwardoń, Aleksandra Suchołbiak, Miłosz Rewekant, Anna Świerczek, Zuzanna Walczak, Bartosz Zawadzki, Tomasz Adam Szczepanowski, Aleksander Gajkowski, Natalia Kornacka, Krzysztof Bednarski
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
